We are a fully integrated protein biopharmaceutical company based in Taiwan, combining an operating model with innovation and invention, trial development, production, manufacturing , and marketing in the international market. Applying the Company’s in-house developed PEGylation technology platform is mainly used in four diseases such as” Hematology, Infectious Diseases, Oncology, and Dermatology”. Our globalization strategies is through "establishing foreign subsidiaries" and "partnering in-licensing, out-licensing and development," recruiting local outstanding talents to engage in clinical trials and marketing strategies, so as to enhance competitive advantage, and strive to build PharmaEssentia into a world-class innovative biopharmaceutical company.

Performance highlights

Corresponding SDGs

01

Our Globalization strategies

Two major globalization strategies:
"Establishing foreign subsidiaries" and "Partnering in-licensing, out-licensing and development"

Three primary strategic pillars:

02

R&D of innovative biopharmaceuticals

R&D potential and results

Pursue animal welfare in Preclinical Animal Experiments Ethics, Clinical Trials Ethics, and Drug Marketing Ethics

Launching international clinical trials to enhance the competitiveness of drugs

03

Partnerships from the Value Chain

Upholding our mission, PharmaEssentia strives to give back to the society and to create values in Taiwan’s biotechnology industry chain. We collaborate with every partner throughout our industry chain based on the spirit of “creating the common good and co-prosperity” to strive toward mutually sustainable value.

The Chapter of Innovation

We are a fully integrated protein biopharmaceutical company based in Taiwan, combiningan operating model with innovation and invention, trial development, production, manufacturing , and marketing in the international market.

Downloads Innovation Report